Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Purpura, Thrombocytopenic, Idiopathic

ClinicalTrials.gov lists 481 trials for Purpura, Thrombocytopenic, Idiopathic or a narrower condition beneath it. Amgen has the most among industry and government lead sponsors, with 18.

MeSH D016553 Hemic and Lymphatic Diseases C15 C20 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 25 Phase 2 Phase 2 130 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 109 Phase 4 Phase 4 26 Not applicable Not applicable 32 Observational Observational 98 Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 25 Phase 2 Phase 2 130 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 109 Phase 4 Phase 4 26 Not applicable Not applicable 32 Observational Observational 98

Trials per phase

1 more section with rows

481 of the 481 trials are tagged with Purpura, Thrombocytopenic, Idiopathic itself; the rest are tagged with a narrower condition beneath it.

Get the Purpura, Thrombocytopenic, Idiopathic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Purpura, Thrombocytopenic, Idiopathic trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 54

1999: 1 trials (Phase 2 1) 2000: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 2001: 2 trials (Phase 3 1, Phase 2 1) 2002: 5 trials (Phase 3 2, Phase 2 2, Phase 1/2 1) 2003: 5 trials (Phase 2/3 1, Phase 2 3, Phase 1/2 1) 2004: 6 trials (Not applicable 1, Phase 3 3, Phase 2 2) 2005: 10 trials (Observational 2, Phase 3 6, Phase 2 1, Phase 1 1) 2006: 9 trials (Observational 1, Phase 3 5, Phase 2 2, Phase 1/2 1) 2007: 16 trials (Observational 2, Phase 3 4, Phase 2 5, Phase 1/2 2, Phase 1 3) 2008: 8 trials (Phase 3 3, Phase 2/3 2, Phase 2 3) 2009: 7 trials (Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 2) 2010: 14 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1 1) 2011: 15 trials (Observational 8, Phase 4 1, Phase 3 4, Phase 1 2) 2012: 21 trials (Observational 7, Not applicable 2, Phase 3 8, Phase 2 3, Phase 1 1) 2013: 12 trials (Observational 5, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1 1) 2014: 16 trials (Observational 3, Phase 3 8, Phase 2 2, Phase 1/2 1, Phase 1 2) 2015: 16 trials (Observational 3, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1/2 3) 2016: 13 trials (Observational 3, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 2) 2017: 17 trials (Observational 4, Not applicable 1, Phase 4 2, Phase 3 4, Phase 2 4, Phase 1 2) 2018: 17 trials (Observational 5, Not applicable 2, Phase 3 3, Phase 2 3, Phase 1/2 2, Phase 1 2) 2019: 22 trials (Observational 8, Not applicable 2, Phase 4 3, Phase 3 5, Phase 2 3, Phase 1 1) 2020: 23 trials (Observational 3, Phase 4 4, Phase 3 6, Phase 2 9, Phase 1 1) 2021: 33 trials (Observational 8, Not applicable 2, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 2) 2022: 34 trials (Observational 6, Not applicable 3, Phase 4 3, Phase 3 8, Phase 2 13, Phase 1 1) 2023: 32 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 17, Phase 1/2 1, Phase 1 3) 2024: 27 trials (Observational 6, Not applicable 3, Phase 3 1, Phase 2 8, Phase 1/2 1, Phase 1 8) 2025: 54 trials (Observational 10, Not applicable 4, Phase 4 2, Phase 3 9, Phase 2/3 2, Phase 2 11, Phase 1/2 8, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 37
2025 54
2024 27
2023 32
2022 34
2021 33
2020 23
2019 22
2018 17
2017 17

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 48 trials starting in 2026 and about 49 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 79 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 218 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Purpura, Thrombocytopenic, Idiopathic trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 47
Phase 1/2 25
Phase 2 130
Phase 2/3 11
Phase 3 109
Phase 4 26
Not applicable 32
Observational 98
Expanded access 3

How many Purpura, Thrombocytopenic, Idiopathic trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 40
Recruiting 87
Enrolling by invitation 2
Active, not recruiting 11
Available 2

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Purpura, Thrombocytopenic, Idiopathic trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Amgen 18
Novartis Pharmaceuticals 17
GlaxoSmithKline 11
Eisai Inc. 8
argenx 8

Which drugs are being tested for Purpura, Thrombocytopenic, Idiopathic? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Eltrombopag 42
Romiplostim 28
RITUXIMAB 25
Avatrombopag 16
Prednisone 11

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 39
rhTPO 9
Daratumumab SC 7
All-Trans Retinoid Acid(ATRA) 6
FOSTAMATIN 5

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Purpura, Thrombocytopenic, Idiopathic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Thrombocytopenia 148 35
Epistaxis 66 21
Pneumonia 56 19
Headache 41 21
Platelet count decreased 34 15

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Purpura, Thrombocytopenic, Idiopathic? (342)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Safety and efficacy of daratumumab in immune thrombocytopenia. Blood advances 2026 Yes
Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. American journal of hematology 2026 Yes
Efficacy and safety of dapsone in adult primary immune thrombocytopenia. Blood advances 2025 Yes
A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. International journal of hematology 2025 Yes
Long-term follow-up of the STOPAGO study. Blood 2025 Yes

Showing 5 of 342 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (14)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Immune thrombocytopenia Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Immune thrombocytopenia Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Immune thrombocytopenia Point prevalence 1-9 / 100 000 United States US Exact
Immune thrombocytopenia Point prevalence 1-9 / 100 000 United States US Exact
Immune thrombocytopenia Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 14 prevalence observations.

Start your 14-day trial Email me all 14 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Immune thrombocytopenia 3002 Exact Orphanet Rare Disease Ontology (ORDO)
Immune thrombocytopenia 3002 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages